The question of whether JAK inhibitor therapy could achieve reduction in CSF3R allele burden was initially addressed by Dao et al. in an aCML patient harboring a CSF3RT618I (along with CBLI383T and KDM6AS114C) mutation167. Here, CSF3R is linked to atypical chronic myeloid leukemia, BCR-ABL1 negative.